SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
Clinical trial NCT03589222 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03589222
- Sponsor
- PETHEMA Foundation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-15
- Primary completion
- 2026-08-01
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.